Literature DB >> 32076119

Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia.

Daniel W Thomson1,2, Nur Hezrin Shahrin1,2, Paul P S Wang2,3, Carol Wadham1,2, Naranie Shanmuganathan1,2,4,5, Hamish S Scott1,2,3,4, Marcel E Dinger6, Timothy P Hughes4,5, Andreas W Schreiber2,3,7, Susan Branford8,9,10,11.   

Abstract

Blast crisis of chronic myeloid leukemia is associated with poor survival and the accumulation of genomic lesions. Using whole-exome and/or RNA sequencing of patients at chronic phase (CP, n = 49), myeloid blast crisis (MBC, n = 19), and lymphoid blast crisis (LBC, n = 20), we found 25 focal gene deletions and 14 fusions in 24 patients in BC. Deletions predominated in LBC (83% of structural variants). Transcriptional analysis identified the upregulation of genes involved in V(D)J recombination, including RAG1/2 and DNTT in LBC. RAG recombination is a reported mediator of IKZF1 deletion. We investigated the extent of RAG-mediated genomic lesions in BC. Molecular hallmarks of RAG activity; DNTT-mediated nucleotide insertions and a RAG-binding motif at structural variants were exclusively found in patients with high RAG expression. Structural variants in 65% of patients in LBC displayed these hallmarks compared with only 5% in MBC. RAG-mediated events included focal deletion and novel fusion of genes associated with hematologic cancer: IKZF1, RUNX1, CDKN2A/B, and RB1. Importantly, 8/8 patients with elevated DNTT at CP diagnosis progressed to LBC by 12 months, potentially enabling early prediction of LBC. This work confirms the central mutagenic role of RAG in LBC and describes potential clinical utility in CML management.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32076119     DOI: 10.1038/s41375-020-0751-y

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  49 in total

Review 1.  The mechanism and regulation of chromosomal V(D)J recombination.

Authors:  Craig H Bassing; Wojciech Swat; Frederick W Alt
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

2.  V(D)J recombinase binding and cleavage of cryptic recombination signal sequences identified from lymphoid malignancies.

Authors:  Ming Zhang; Patrick C Swanson
Journal:  J Biol Chem       Date:  2008-01-09       Impact factor: 5.157

3.  Nucleotide Composition of Human Ig Nontemplated Regions Depends on Trimming of the Flanking Gene Segments, and Terminal Deoxynucleotidyl Transferase Favors Adding Cytosine, Not Guanosine, in Most VDJ Rearrangements.

Authors:  Tina Funck; Mike Bogetofte Barnkob; Nanna Holm; Line Ohm-Laursen; Camilla Slot Mehlum; Sören Möller; Torben Barington
Journal:  J Immunol       Date:  2018-08-10       Impact factor: 5.422

4.  Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Authors:  Andreas Hochhaus; Richard A Larson; François Guilhot; Jerald P Radich; Susan Branford; Timothy P Hughes; Michele Baccarani; Michael W Deininger; Francisco Cervantes; Satoko Fujihara; Christine-Elke Ortmann; Hans D Menssen; Hagop Kantarjian; Stephen G O'Brien; Brian J Druker
Journal:  N Engl J Med       Date:  2017-03-09       Impact factor: 91.245

5.  How I treat CML blast crisis.

Authors:  Rüdiger Hehlmann
Journal:  Blood       Date:  2012-05-31       Impact factor: 22.113

6.  Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

Authors:  Z Chen; J E Cortes; J L Jorgensen; W Wang; C C Yin; M J You; E Jabbour; H M Kantarjian; L J Medeiros; S Hu
Journal:  Leukemia       Date:  2016-02-03       Impact factor: 11.528

7.  Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.

Authors:  Susan Branford; Paul Wang; David T Yeung; Daniel Thomson; Adrian Purins; Carol Wadham; Nur Hezrin Shahrin; Justine E Marum; Nathalie Nataren; Wendy T Parker; Joel Geoghegan; Jinghua Feng; Naranie Shanmuganathan; Martin C Mueller; Christian Dietz; Doris Stangl; Zoe Donaldson; Haley Altamura; Jasmina Georgievski; Jodi Braley; Anna Brown; Christopher Hahn; Ieuan Walker; Soo-Hyun Kim; Soo-Young Choi; Sa-Hee Park; Dong-Wook Kim; Deborah L White; Agnes S M Yong; David M Ross; Hamish S Scott; Andreas W Schreiber; Timothy P Hughes
Journal:  Blood       Date:  2018-07-02       Impact factor: 22.113

Review 8.  Molecular mechanisms of antibody somatic hypermutation.

Authors:  Javier M Di Noia; Michael S Neuberger
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

9.  RAG Represents a Widespread Threat to the Lymphocyte Genome.

Authors:  Grace Teng; Yaakov Maman; Wolfgang Resch; Min Kim; Arito Yamane; Jason Qian; Kyong-Rim Kieffer-Kwon; Malay Mandal; Yanhong Ji; Eric Meffre; Marcus R Clark; Lindsay G Cowell; Rafael Casellas; David G Schatz
Journal:  Cell       Date:  2015-07-30       Impact factor: 41.582

10.  Two Mutually Exclusive Local Chromatin States Drive Efficient V(D)J Recombination.

Authors:  Daniel J Bolland; Hashem Koohy; Andrew L Wood; Louise S Matheson; Felix Krueger; Michael J T Stubbington; Amanda Baizan-Edge; Peter Chovanec; Bryony A Stubbs; Kristina Tabbada; Simon R Andrews; Mikhail Spivakov; Anne E Corcoran
Journal:  Cell Rep       Date:  2016-06-02       Impact factor: 9.423

View more
  7 in total

Review 1.  Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication.

Authors:  Nur Hezrin Shahrin; Carol Wadham; Susan Branford
Journal:  Curr Hematol Malig Rep       Date:  2022-08-06       Impact factor: 4.213

2.  RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.

Authors:  Meng Yuan; Yang Wang; Mengting Qin; Xiaohui Zhao; Xiaodong Chen; Dandan Li; Yinsha Miao; Wood Otieno Odhiambo; Huasheng Liu; Yunfeng Ma; Yanhong Ji
Journal:  Cancer Sci       Date:  2021-05-18       Impact factor: 6.716

Review 3.  Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.

Authors:  Afaf E G Osman; Michael W Deininger
Journal:  Blood Rev       Date:  2021-03-16       Impact factor: 10.626

Review 4.  Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia.

Authors:  Adelina Fernandes; Naranie Shanmuganathan; Susan Branford
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

Review 5.  Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers.

Authors:  Vaidehi Krishnan; Dennis Dong Hwan Kim; Timothy P Hughes; Susan Branford; S Tiong Ong
Journal:  Haematologica       Date:  2022-02-01       Impact factor: 9.941

Review 6.  Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage-Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities.

Authors:  Lukasz Komorowski; Klaudyna Fidyt; Elżbieta Patkowska; Malgorzata Firczuk
Journal:  Int J Mol Sci       Date:  2020-08-12       Impact factor: 5.923

7.  RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.

Authors:  Matti Kankainen; Satu Mustjoki; Shady Adnan Awad; Olli Dufva; Aleksandr Ianevski; Bishwa Ghimire; Jan Koski; Pilvi Maliniemi; Daniel Thomson; Andreas Schreiber; Caroline A Heckman; Perttu Koskenvesa; Matti Korhonen; Kimmo Porkka; Susan Branford; Tero Aittokallio
Journal:  Leukemia       Date:  2020-08-11       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.